IL-6抑制剂托西利祖马布在骨质整合过程中减少了在植入物周围的骨吸收,有细菌感染:在子身上进行的一项试点研究
概括
托西利祖马布是一种干白素-6 (IL-6) 抑制剂,有效地减少了子在骨质整合过程中在植入物周围的细菌感染引起的骨损失. 这项研究强调了其在损害骨环境中提高植入成功率的潜力.
科学领域:
- 生物材料科学 生物材料科学
- 免疫学 免疫学 免疫学
- 口腔和牙面部外科手术
背景情况:
- 细菌感染可能会危及骨质整合,并导致牙植入物周围的骨质再吸收.
- 介质素-6 (IL-6) 在炎症性骨损失中起着重要作用.
- 向IL-6可能提供一种治疗策略,以减轻在骨质整合过程中与感染相关的骨损失.
研究的目的:
- 为了研究tocilizumab的疗效,一个IL-6抑制剂,在子模型的细菌感染中,在骨质整合过程中防止植入物周围的骨质再吸收.
主要方法:
- 24只子接受了下前牙切除和随后的植入物安置.
- 动物被分为四组:空白对照,负对照 (丝结合),阳性对照 (结合 + 米诺环素) 和实验 (结合 + 托西利祖马布).
- 骨体积,IL-6表达,RANKL表达和新的骨形成使用微CT,免疫组织化学和组织学进行了分析.
主要成果:
- 与对照组相比,tocilizumab组的骨体积与总体积比率 (BV/TV) 显著增加.
- 托西利祖马布治疗导致核因子-κB连接体 (RANKL) 表达的最低受体激活剂.
- 组织学分析显示,托西利祖马布组的植入物上有大量新的骨形成,骨再吸收减少.
结论:
- 托西利祖马布在骨质整合过程中证明了对细菌感染引起的植入物周围骨损失的保护作用.
- 抑制IL-6信号传递可能是一个可行的方法,以提高植入物稳定性和感染部位的存活率.
相关概念视频
01:30Bacterial Signaling
32.0K
Bacterial signaling can occur within bacteria (intracellular) or between bacteria (intercellular). At times, a group of bacteria behaves like a community. To achieve this, they engage in quorum sensing, the perception of higher cell density that causes changes in gene expression. Quorum sensing involves both extracellular and intracellular signaling. The signaling cascade starts with a molecule called an autoinducer (AI). Individual bacteria produce AIs that move out of the bacterial cell...
32.0K
01:24T Cell Types and Functions
999
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
999
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
01:27Tumor Immunotherapy
511
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
511
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156